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Birth weight and body mass index
z-score in childhood brain tumors:
A cross-sectional study
Kuan-Wen Wang 1,2,3, Russell J. de Souza3,4, Adam Fleming1,3,5, Donna L. Johnston6,
Shayna M. Zelcer7, Shahrad Rod Rassekh8, Sarah Burrow9, Lehana Thabane4,10,11,12 &
M. Constantine Samaan1,2,3,4
Children with brain tumors (CBT) are at higher risk of cardiovascular disease and type 2 diabetes
compared to the general population, in which birth weight is a risk factor for these diseases. However,
this is not known in CBT. The primary aim of this study was to explore the association between birth
weight and body mass measures in CBT, compared to non-cancer controls. This is a secondary data
analysis using cross-sectional data from the CanDECIDE study (n = 78 CBT and n = 133 non-cancer
controls). Age, sex, and birth weight (grams) were self-reported, and confirmed through examination
of the medical records. Body mass index (BMI) was calculated from height and weight measures and
reported as kg/m2. BMI z-scores were obtained for subjects under the age of 20 years. Multivariable
linear regression was used to evaluate the relationship between birth weight and BMI and BMI z-score,
adjusted for age, sex, puberty, and fat mass percentage. Higher birth weight was associated with higher
BMI and BMI z-score among CBT and controls. In conclusion, birth weight is a risk factor for higher body
mass during childhood in CBT, and this may help the identification of children at risk of future obesity
and cardiometabolic risk.
Brain tumors are the most common cause of cancer-related deaths in children1,2. While brain tumors are a heterogeneous group with some fairly aggressive subtypes, advancements in imaging and therapeutic breakthroughs
have increased the number of children surviving these tumors1,2. This important milestone has been offset by
the emergence of co-morbidities and premature mortality in survivors3–7. While traditionally reported outcome
determinants include tumor recurrence and secondary tumors, recent evidence suggests that children with brain
tumors (CBT) are at higher risk of premature cardiovascular diseases including hypertension, cerebrovascular
events and type 2 diabetes compared to non-cancer controls8–10. While the mechanisms leading to these cardiometabolic disorders are not well understood, the combined burden of the tumor and treatment with these
emerging chronic disorders will increasingly contribute to adverse outcomes in CBT as these survivors live longer
and get older.
The global obesity epidemic is the main catalyst of cardiometabolic disorders in the general population11–14,
and the association of obesity with future type 2 diabetes and cardiovascular diseases has been tracked to childhood15. Defining the determinants of obesity, cardiovascular disease and diabetes in CBT will permit the prioritization of children who need early intervention to improve survivors’ quality of life and lifespan.
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Control

CBT

Variables

Total (n = 133) Mean ± SD

Total (n = 78) Mean ± SD

p-value

Age at enrollment (years)

14.10 ± 2.70

15.10 ± 7.30

0.64

Female

60 (45.10)

33 (42.30)

0.69

Male

73 (54.90)

45 (57.70)

European

91 (68.40)

59 (75.60)

Others

42 (31.60)

19 (24.40)

Pre-pubertal

17 (12.80)

24 (30.80)

Pubertal

116 (87.20)

54 (69.20)

Height (cm)

162.70 ± 15.00

151.00 ± 25.20

Sex, No. (%)

Ethnicity, No. (%)
0.26

Puberty, No. (%)
0.001
<0.001

Weight (kg)

60.00 ± 21.40

53.40 ± 24.90

0.007

BMI (kg/m2)

21.70 ± 4.20

21.40 ± 4.70

0.49

BMI z-score

0.49 ± 1.10

0.47 ± 1.10

0.92

BMI%ile < 85 or BMI < 25

88 (66.20)

49 (62.80)

0.62

BMI%ile ≥ 85 or BMI ≥ 25

45 (33.80)

29 (37.20)

BMI category, No. (%)

Fat mass percentage (%)

22.40 ± 9.80

25.80 ± 9.60

0.01

Birth weight (g)

3491.30 ± 487.40

3436.60 ± 516.50

0.43

Pregnancy gestation (weeks)

38.90 ± 2.30

39.90 ± 1.80

0.001

Table 1. Characteristics of study population. Abbreviations: CBT, Children with Brain Tumors; SD, Standard
Deviation; BMI, Body Mass Index.

Over the past two decades, evidence has validated the role of birth weight as a risk factor for adult obesity
and cardiometabolic disorders16,17; however, it is unclear if birth weight in CBT is a risk factor for obesity during
childhood. Given that CBT have excess adiposity in comparison to non-cancer controls18, it may be a potential early predictor of further adverse cardiometabolic outcomes. In addition, while CBT have similar rates of
overweight/obesity when compared to non-cancer controls, this still leaves one-in-four CBT in the overweight/
obese category based on body mass measures19. Body mass index (BMI) is the most used screening tool to assess
obesity risk, and may still be a predictor of future cardiometabolic risk, as these children get older. Therefore, the
primary aim of this paper was to explore if birth weight is a risk factor for higher body mass in CBT, compared to
non-cancer controls.

Results

Population characteristics. We included 78 CBT (n = 33 females [42.3%]) and 133 non-cancer controls
(n = 60 females, [45.1%]) in this study. The characteristics of the study population are shown in Table 1. The two
groups have similar age, sex, ethnicity, BMI, BMI z-score, and birth weight distribution. However, the control
group was taller and weighed more than CBT. On the other hand, CBT had higher fat mass percentage (%FM)
(CBT 25.80 ± 9.60% versus controls 22.40 ± 9.80%, p = 0.01).
Participants born at full-term comprised the largest groups (CBT n = 45 [57.70%]; controls n = 65 [48.90%]).
More controls were born pre-term (CBT n = 3 [3.80%]; controls n = 21 [15.80%], p = 0.008) while both have
similar distribution for early-term (CBT n = 10 [12.80%]; controls n = 24 [18.00%], p = 0.32) and late-term (CBT
n = 20 [25.60%]; controls n = 23 [17.30%], p = 0.15).
The majority of both CBT and controls were born appropriate for gestational age (AGA) (CBT n = 60
[76.90%]; controls n = 90 [67.70%]). Both groups had a similar distribution for those who were born small for
gestational age (SGA) (CBT n = 11 [14.10%]; controls n = 12 [9.00%], p = 0.25) while large for gestational age
(LGA) was more common in controls (CBT n = 7 [9.00%]; controls n = 31 [23.30%], p = 0.009). Maternal gestational diabetes was reported in two CBT (2.60%) and in one control (0.80%), while preeclampsia was reported in
five CBT (6.40%) and 10 controls (7.50%).
The majority of the subjects had normal birth weight (CBT n = 62 [79.50%]; controls n = 104 [78.20%]). Six
CBT (7.70%) and six controls (4.50%) were born with a low birth weight (<2500 grams). High birth weight
(>4000 grams) was reported in ten CBT (12.80%) and 23 controls (17.30%).
Tumor characteristics and treatments. Brain tumor characteristics and therapeutic modalities
are reported in Table 2. The most common tumors in this study population were low-grade gliomas (n = 45
[57.70%]). Brain tumors were equally distributed between supratentorial and infratentorial regions. The treatments used in participants were surgery alone (n = 25 [32.00%]), and a combination of surgery, radiotherapy, and chemotherapy (n = 24 [30.80%]). Other single treatment options included radiotherapy alone (n = 2
[2.60%]), and chemotherapy alone (n = 7 [9.00%]). Other combinations of treatment modalities were surgery and
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Variables

No. (%)

Brain tumor type
Non-NF-1, low grade glioma

34 (43.60)

PNET/Medulloblastoma

17 (21.80)

NF-1, low grade glioma

11 (14.10)

CNS germ cell tumors

6 (7.70)

Subependymal giant cell astrocytoma

3 (3.80)

Ependymoma

2 (2.60)

Craniopharyngioma

2 (2.60)

Meningioma

1 (1.30)

Atypical teratoid/rhabdoid tumor

1 (1.30)

Choroid plexus papilloma

1 (1.30)

Brain tumor location
Supratentorial

36 (46.20)

Infratentorial

42 (53.80)

Brain tumor treatments
Surgery

60 (76.90)

Radiotherapy

33 (42.30)

Chemotherapy

37 (47.40)

No treatment

8 (10.30)

Table 2. Brain tumor type, location, and treatments (n = 78). Abbreviations: CNS, Central Nervous System;
PNET, Primitive Neuroectodermal Tumor; NF-1, Neurofibromatosis Type 1.

BMI
Main Effect

Interaction

Variables

Estimated β (95% CI)

p-value

Estimated β (95% CI)

Birth weight

0.18 (0.09,0.27)

<0.001

0.17 (0.06,0.28)

0.003

p-value

Brain tumor status

−0.03 (−0.04, −0.01)

<0.001

−0.11 (−0.73,0.51)

0.73

Interactiona

—

—

0.02 (−0.15,0.20)

0.80

BMI z-score
Birth weight

2.81 (1.54,4.09)

<0.001

Brain tumor status

−0.33 (−0.51, −0.14)

0.001

Interactiona

—

—

2.10 (0.52,3.68)

0.009

−7.48 (−16.83,1.86)

0.12

2.02 (−0.62,4.67)

0.13

Table 3. Interaction analysis of body mass measures and birth weight in CBT and non-cancer controls.
Abbreviations: CBT, Children with Brain Tumors; BMI, Body Mass Index; CI, Confidence Interval. Models were
adjusted for age, sex, puberty, fat mass percentage. aThe interaction term was birth weight*brain tumors status
(yes/no).

radiotherapy (n = 6 [7.70%]), surgery and chemotherapy (n = 5 [6.40%]), and radiotherapy and chemotherapy
(n = 1 [1.30%]). Eight CBT (10.20%) were managed conservatively at the time of inclusion in the study.

The association of birth weight and body mass. To explore the association of birth weight with body
mass, we performed multivariable regression analyses in CBT, adjusted for age, sex, puberty, and %FM. For
every unit increase in birth weight, BMI increased by 0.18 units (95%CI 0.03,0.33; p = 0.02) in CBT and by 0.17
units (95%CI 0.07,0.27; p = 0.001) in controls. Similarly, for every unit increase in birth weight, BMI z-score also
increased by 3.69 units (95%CI 1.12,6.25; p = 0.006) in CBT and by 2.15 units (95%CI 0.75,3.55; p = 0.003) in
controls.
To determine if the association between birth weight and body mass differs between CBT and controls, an
interaction term (birth weight*brain tumor status) was introduced (Table 3). Birth weight is associated with body
mass, and the effect of birth weight on body mass was similar between CBT and controls (BMI β = 0.02; 95% CI
−0.15, 0.20; p = 0.80; BMI z-score β = 2.02; 95% CI −0.62,4.67; p = 0.13).

Discussion

The emergence of cardiovascular diseases and type 2 diabetes in survivors of childhood brain tumors are likely
to contribute to adverse prognoses, and there is an urgent need to identify the drivers of these outcomes to mitigate their effects on the life span and quality of life. In this study, we demonstrate that birth weight is a risk factor
for higher body mass in CBT during childhood, and this relationship was similar to that noted in non-cancer
controls.
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The influence of the in- and ex-utero environments on the risk of obesity and cardiometabolic risk is an
important determinant of health outcomes, based on evidence from studies in the general population20–22. One of
the potential early and feasible measures that forecast these outcomes is birth weight.
Birth weight is driven by several factors, including genes that determine body size and growth, and the intrauterine environment23. It is estimated that 10–40% of birth weight is driven by genetic factors, with several loci
identified to suggest genetic links with body weight and mass23,24. In addition, fetal metabolic programing in utero
in response to the intrauterine environment contributes to cardiometabolic health postnatally through epigenetic
and other mechanisms25.
The exposure of an embryo to an adverse intrauterine environment and excess metabolic stress leads to the
re-programming of the metabolic pathways, to adapt to in-utero scarcity or excess of nutrients22,26. Clinically, this
manifests with infants being born small or large for gestational age27. However, it is likely that at intermediate
stages of metabolic stress, some babies may have a birth weight within the normal range, but have been exposed
to an environment that can alter their metabolic trajectory28.
The evidence for the association of certain categories of birth weight with adult BMI and cardiometabolic
disorders was highlighted in studies from David Barker and the Dutch famine cohort and others, and showed
that birth weight and maternal-fetal undernutrition was linked to low birth weight that was associated with adult
obesity and adverse cardiometabolic outcomes29–34.
In addition, the link between birth weight and obesity was highlighted in previous reports showing that those
born SGA or LGA to be at risk of adult obesity22. However, recent studies report that in those with a birth weight
that is sometimes within the normal range, or who have high birth weight (>4000 grams), are at risk of adult
obesity28,35,36. Contrary to previous evidence37–39, some studies did not show linear, J-shaped or U-shaped associations of birth weight with adult obesity35,36.
Our data show a positive relationship between birth weight and body mass measures in CBT and controls in
childhood. This is congruent with recent large-scale studies that have provided further evidence of similar results
in the general pediatric population27,40,41. Birth weight may help identify those CBT who are at risk of adult obesity. Detailed study of growth paths and longer follow-up period are needed to determine if birth weight is a risk
factor for obesity in CBT as they reach adulthood.
While available evidence suggest that obese children are at risk of becoming obese adults42–44, the association
between birth weight, childhood BMI and future cardiometabolic risk is more complex45. It has been reported
that birth weight below 3.4 kg, which is still considered appropriate for gestational age, and high BMI during
childhood were independently associated with increased risk of coronary heart disease20. The association between
low birth weight and type 2 diabetes was also reported46,47. The evidence indicates that both birth weight and BMI
need to be scrutinized in CBT and controls to identify subjects who are at an increased risk of cardiometabolic
disorders, as they appear to be independently linked to these outcomes.
While the majority of evidence has focused on high (>4000 g) and low (<2500 g) birth weight and its association with obesity risk28,35, it is less clear how a normal birth weight affect this trajectory of adult obesity and cardiometabolic outcomes in CBT. Our data suggest that as weight trends higher while still within the normal range,
this represents a risk factor for higher body mass. However, more prospective data sets are required to validate
this observation and its association with cardiometabolic outcomes in CBT.
One of the strengths of our study is the inclusion of non-cancer controls to provide a comparison group. It is a
strength to have this control group because when all is equal for birth weight between cases and controls, we can
test the effect of having cancer and therapy on the association between birth weight and BMI.
It has been shown that CBT have increased adiposity early in life post completion of therapy, and are at higher
risk of cardiovascular diseases and diabetes compared to the general population, despite having similar BMI to
controls9,18,48. CBT can have disproportionate effects of their tumor and its treatment on cardiometabolic outcomes at a similar obesity rate, and birth weight may be a potential risk factor for these outcomes18,49,50.
There are several limitations in this study. We did not have sufficient power to determine the association of
birth weight with young adult BMI, as the number of young adult subjects in our study was small. While we
demonstrate that birth weight is positively associated with body mass measures in adolescence, our data does
not distinguish whether this is a result of the expansion of lean body mass or fat mass, as BMI is a measure of
total body mass. A recent study showed that birth weight was associated with fat-free mass, but not with fat mass
among children and adolescents51. This will require further clarification in future studies.
This analysis is cross-sectional and therefore it is not clear if subjects were overweight or obese before their
brain tumor diagnoses. In addition, the data used in the study were collected as a part of the Canadian Study of
Determinants of Endometabolic Health in Children (CanDECIDE study)52, and this paper is not related to the
primary study question. Therefore, the study was not designed to answer this question specifically. Prospective
collection of data from diagnosis onwards and correlating growth data with those from earlier time points may
help define growth patterns of those survivors at risk of obesity.
In conclusion, cardiometabolic disorders are occurring at a relatively young age in CBT, and are emerging
as significant morbidities and as potential determinants of longevity5,9,48. Our results suggest that birth weight
is a risk factor for higher body mass in CBT in the early years post treatment. Future studies need to focus on
determining the early origins of obesity and cardiometabolic risk in survivors. This will help identify survivors
who are at particular risk of these complications, and birth weight may be one of the risk markers used to stratify
cardiometabolic risk in CBT.

Methods

Participants.

This secondary data analysis used data that were collected as a part of the CanDECIDE Study.
This is a cohort study conducted at McMaster Children’s Hospital in Hamilton, Ontario, Canada52,53.
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Briefly, we recruited participants who were 5 years and older, with no history of autoimmune diseases or
infection, and have not received immunosuppressive therapy for at least 15 days prior to enrollment. Participants
were consecutively recruited and the study recruitment took place between November 2012-March 2017. The
Hamilton Integrated Research Ethics Board approved the study, and participants provided written informed consent. The study procedures were carried out in accordance with relevant guidelines and legal regulations.

Clinical Data and Anthropometric measures. The collected data included age, sex, ethnicity, puberty,
pregnancy gestation, maternal gestational diabetes and preeclampsia, and reported birth weight using standardized questionnaires52,53. While reported birth weight correlates with measured birth weight54, the reported birth
weight was verified from the medical records. In CBT, we also collected data regarding tumor type, location,
sidedness and treatment modalities.
Gestation was defined for those born at less than 37 weeks as preterm, between 37–38 + 6/40 weeks as early
term, 39–40 + 6/40 weeks as full term, and 41–41 + 6/40 weeks as late term gestations55. Normal birth weight was
defined to be between 2500–4000 grams56. Infants born SGA were defined as those with a birth weight below
the10th percentile, AGA as 10th-90th percentile, and LGA as above 90th percentile using Canadian reference
ranges57.
Anthropometric measurements performed included height measured to 0.1 cm using a stadiometer, and
weight measured using an electronic weighing scale (Seca, USA) and measured to the closest 0.1 kg. BMI was calculated in kg/m2 for all subjects. For those under 20 years of age (CBT n = 62, controls n = 133), BMI percentile
and BMI z-scores were also obtained based on the Children’s BMI Tool for Schools58 and the Centers for Disease
Control and Prevention (CDC) growth chart59, respectively. Subjects with BMI ≥ 85th –<95th percentile were
classified as overweight, and those above 95th percentile were classified as obese60.
Adiposity was determined by measuring fat mass percentage (%FM) using the Tanita body fat monitor (Tanita
Corporation, Illinois, USA) for those under 18 years of age, and with the InBody520 body composition analyzer
(Biospace Co., Ltd, Korea) for those 18 years and older as previously reported18.
Statistical Analysis.

All analyses were performed using PASW version 18 statistical package 61.
Kolmogorov-Smirnov test was used to assess the normality of data distribution, and data were log-transformed
if they were non-normally distributed. Outliers were examined with box plot and visual inspection of extreme
values. Multiple imputations was done for missing data62. Mean and standard deviation (SD) were reported for
continuous variables, while the categorical variables were reported as counts with percentages. Independent sample t-tests were used to compare continuous variables between CBT and non-cancer controls while chi-square
tests were performed to compare categorical variables.
To explore the association between birth weight and body mass measures in CBT, multivariable linear regression analysis was performed in this group. The dependent variables included BMI and BMI z-scores in separate
models. The independent variables included birth weight, age, sex, puberty, and %FM.
The relationship between birth weight and body mass in CBT and non-cancer controls was explored by adding
an interaction term (birth weight*brain tumor status). Both CBT and non-cancer controls were included in the
regression analysis.
Results were presented as estimated β coefficients, 95% confidence intervals (CI), and associated p-value. The
criterion for statistical significance was set at alpha = 0.05.

Data availability.
sponding author.

The dataset used for statistical analysis for the current study is available from the corre-
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